Intellia Therapeutics, Inc. (NTLA) Revenue History
Annual and quarterly revenue from 2014 to present
NTLA Revenue Over Time (2014–2025)
NTLA Revenue Growth History
8 of 10 years with positive growth- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- +172.7%
- FY2017 revenue growth
- +58.5%
- FY2018 revenue growth
- +16.5%
- FY2019 revenue growth
- +41.6%
- FY2020 revenue growth
- +34.5%
- FY2021 revenue growth
- -43.0%
- FY2022 revenue growth
- +57.7%
- FY2023 revenue growth
- -30.4%
- FY2024 revenue growth
- +59.6%
- FY2025 revenue growth
- +16.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $15.0M | -9.5% |
| Q4 2025 | $23.0M | +78.8% |
| Q3 2025 | $13.8M | +51.3% |
| Q2 2025 | $14.2M | +104.8% |
| Q1 2025 | $16.6M | -42.5% |
| Q4 2024 | $12.9M | +771.6% |
| Q3 2024 | $9.1M | -24.0% |
| Q2 2024 | $7.0M | -48.8% |
Multi-year avg. share of annual revenue by fiscal quarter
NTLA Revenue Analysis (2014–2025)
Current Revenue & Growth
As of June 21, 2026, Intellia Therapeutics, Inc. (NTLA) generated trailing twelve-month (TTM) revenue of $66.1 million, reflecting moderate decline in growth of -9.5% year-over-year. The most recent quarter (Q1 2026) recorded $15.0 million in revenue, down 34.6% sequentially.
Historical Growth Trajectory
NTLA's 5-year compound annual growth rate (CAGR) stands at +3.1%, indicating moderate growth over time. The 3-year CAGR of +9.1% exceeds the 5-year average, indicating an acceleration in the most recent period. Intellia Therapeutics, Inc.'s highest annual revenue of $67.7 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including EDIT (+8.0% YoY), CRSP (-88.9% YoY), and BEAM (+108.0% YoY) — NTLA has underperformed the peer group in revenue growth. Compare NTLA vs EDIT →
NTLA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NTLACurrent | $66M | -9.5% | +3.1% | -651.7% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 SGMO | $40M | -45.8% | -19.7% | -273.1% |
NTLA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $67.7M | +16.9% | $51.7M | 76.5% | $-440,990,000 | -651.7% |
| 2024 | $57.9M | +59.6% | $47.6M | 82.2% | $-534,263,000 | -923.1% |
| 2023 | $36.3M | -30.4% | $27.3M | 75.3% | $-515,291,000 | -1420.5% |
| 2022 | $52.1M | +57.7% | $44.5M | 85.5% | $-458,164,000 | -879.0% |
| 2021 | $33.1M | -43.0% | $26.2M | 79.2% | $-267,850,000 | -810.4% |
| 2020 | $58.0M | +34.5% | $-92,414,000 | -159.4% | $-136,583,000 | -235.5% |
| 2019 | $43.1M | +41.6% | $-65,310,000 | -151.5% | $-106,368,000 | -246.8% |
| 2018 | $30.4M | +16.5% | $-58,681,000 | -192.8% | $-90,870,000 | -298.6% |
| 2017 | $26.1M | +58.5% | $-41,530,000 | -159.0% | $-69,555,000 | -266.3% |
| 2016 | $16.5M | +172.7% | $-15,361,000 | -93.2% | $-32,159,000 | -195.2% |
| 2015 | $6.0M | - | $-5,126,000 | -84.8% | $-13,409,000 | -221.9% |
| 2014 | $0 | - | $-1,657,500 | - | $-5,226,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NTLA — Frequently Asked Questions
Quick answers to the most common questions about buying NTLA stock.
Is NTLA's revenue growth accelerating or slowing?
NTLA revenue is declining -9.5% year-over-year. TTM revenue fell to $66M, contrasting with the 5-year CAGR of +3.1%. The reversal reflects either macro headwinds or company-specific challenges.
What is NTLA's revenue history from 2014 to 2026?
Intellia Therapeutics, Inc. (NTLA) revenue history spans 2014 to 2026. TTM revenue as of 2026 is $66M, growing at -9.5% YoY. The 5-year CAGR is +3.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NTLA's long-term revenue growth rate (CAGR)?
Intellia Therapeutics, Inc.'s 5-year revenue CAGR of +3.1% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -9.5% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NTLA.
Why does NTLA's quarterly revenue fluctuate?
NTLA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Intellia Therapeutics, Inc.'s revenue data from 2014 to 2026 shows full historical quarterly detail on this page.
How is NTLA's revenue distributed by segment?
NTLA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NTLA's revenue compare to industry peers?
Intellia Therapeutics, Inc. (NTLA) with TTM revenue of $66M and -9.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.